Drugs / Stalevo
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Stalevo | — | 2003-10-17 | europa.eu ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01070628 | Dec 2009 → Feb 2010 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04952194 | Jan 2022 → Dec 2023 | Parkinson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT00462007 | Sep 2006 → Aug 2007 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02452606 | Mar 2015 → May 2017 | Parkinson disease, sleep disorder | Asan Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01766258 Comparator | May 2011 → Aug 2012 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stalevo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04952194 ↗ |
| Route | Oral | “Oral 3-4 daily doses for 6 weeks” NCT00462007 ↗ |